o(6)-benzylguanine has been researched along with Benign Neoplasms, Brain in 30 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 7.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "Resistance to temozolomide (TMZ) based chemotherapy in glioblastoma multiforme (GBM) has been attributed to the upregulation of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ( Chiarelli, PA; Ellenbogen, RG; Fang, C; Hatzinger, SJ; Kievit, FM; Silber, JR; Stephen, ZR; Veiseh, O; Wang, K; Zhang, M, 2014) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 3.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| " Single-dose temozolomide at five dosage levels (267, 355, 472, 628, and 835 mg/m(2)) was given at least 6 h after completion of O(6)-benzylguanine bolus." | 2.73 | Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ( Boyett, JM; Broniscer, A; Danks, MK; Friedman, HS; Gajjar, A; Goldman, S; Gururangan, S; Kun, LE; MacDonald, TJ; Packer, RJ; Poussaint, TY; Stewart, CF; Wallace, D, 2007) |
| "To report the results of the first pharmacokinetic study in pediatric patients of O(6)-benzylguanine (O(6)BG), which irreversibly inactivates the DNA repair protein alkylguanine-alkyltransferase, thus enhancing the cytotoxicity of nitrosoureas." | 2.71 | Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. ( Adams, D; Aleksic, A; Berg, S; Bernstein, M; Blaney, S; Neville, K; Thompson, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (33.33) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 4 (13.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A | 1 |
| Henderson, FC | 1 |
| Alshareef, M | 1 |
| Porto, GBF | 1 |
| Kanginakudru, I | 1 |
| Infinger, LK | 1 |
| Vandergrift, WA | 1 |
| Lindhorst, SM | 1 |
| Varma, AK | 1 |
| Patel, SJ | 1 |
| Cachia, D | 1 |
| Kramer, B | 1 |
| Singh, R | 1 |
| Wischusen, J | 1 |
| Dent, R | 1 |
| Rush, A | 1 |
| Middlemiss, S | 1 |
| Ching, YW | 1 |
| Alexander, IE | 1 |
| McCowage, G | 1 |
| Adair, JE | 1 |
| Johnston, SK | 1 |
| Mrugala, MM | 1 |
| Beard, BC | 1 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Hawkins-Daarud, A | 1 |
| Gori, JL | 1 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Rockne, RC | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 1 |
| Swanson, KR | 1 |
| Kiem, HP | 1 |
| Stephen, ZR | 1 |
| Kievit, FM | 1 |
| Veiseh, O | 1 |
| Chiarelli, PA | 1 |
| Fang, C | 1 |
| Wang, K | 1 |
| Hatzinger, SJ | 1 |
| Ellenbogen, RG | 1 |
| Silber, JR | 2 |
| Zhang, M | 1 |
| Liu, C | 1 |
| Yao, S | 1 |
| Li, X | 1 |
| Wang, F | 1 |
| Jiang, Y | 1 |
| Juillerat-Jeanneret, L | 1 |
| Bernasconi, CC | 1 |
| Bricod, C | 1 |
| Gros, S | 1 |
| Trepey, S | 1 |
| Benhattar, J | 1 |
| Janzer, RC | 1 |
| Quinn, JA | 6 |
| Jiang, SX | 4 |
| Carter, J | 1 |
| Reardon, DA | 6 |
| Desjardins, A | 5 |
| Vredenburgh, JJ | 4 |
| Rich, JN | 4 |
| Gururangan, S | 7 |
| Friedman, AH | 6 |
| Bigner, DD | 8 |
| Sampson, JH | 6 |
| McLendon, RE | 8 |
| Herndon, JE | 7 |
| Threatt, S | 1 |
| Friedman, HS | 11 |
| Walker, A | 2 |
| Kreklau, EL | 2 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Erickson, LC | 2 |
| Neville, K | 1 |
| Blaney, S | 1 |
| Bernstein, M | 1 |
| Thompson, P | 1 |
| Adams, D | 1 |
| Aleksic, A | 1 |
| Berg, S | 1 |
| Bacolod, MD | 1 |
| Johnson, SP | 1 |
| Pegg, AE | 7 |
| Dolan, ME | 10 |
| Moschel, RC | 7 |
| Bullock, NS | 1 |
| Fang, Q | 1 |
| Colvin, OM | 2 |
| Modrich, P | 1 |
| Weingart, J | 3 |
| Brem, H | 2 |
| Delaney, SM | 2 |
| Vredenburgh, J | 1 |
| Rich, J | 2 |
| Birch, R | 1 |
| Provenzale, JM | 2 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Tourt-Uhlig, S | 2 |
| Koch, D | 1 |
| Hundsberger, T | 1 |
| Boor, S | 1 |
| Kaina, B | 1 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Rosenblum, ML | 1 |
| Olivi, A | 1 |
| Judy, K | 1 |
| Tatter, SB | 1 |
| Broniscer, A | 1 |
| MacDonald, TJ | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Stewart, CF | 1 |
| Wallace, D | 1 |
| Danks, MK | 1 |
| Poussaint, TY | 1 |
| Kun, LE | 1 |
| Boyett, JM | 1 |
| Gajjar, A | 1 |
| Mineura, K | 3 |
| Izumi, I | 2 |
| Watanabe, K | 2 |
| Kowada, M | 3 |
| Kohda, K | 3 |
| Ikenaga, M | 2 |
| Koyama, K | 1 |
| Terashima, I | 2 |
| Felker, GM | 1 |
| Schold, C | 1 |
| Sarkar, A | 1 |
| Gonzalez, GG | 1 |
| Marton, LJ | 1 |
| Deen, DF | 1 |
| Kurpad, SN | 1 |
| Archer, GE | 1 |
| Fukuchi, M | 1 |
| Bobola, MS | 1 |
| Tseng, SH | 1 |
| Blank, A | 1 |
| Berger, MS | 1 |
| Kokkinakis, DM | 1 |
| Pluda, J | 2 |
| Cokgor, I | 1 |
| Haglund, MM | 2 |
| Ashley, DM | 1 |
| Kerby, T | 1 |
| Schold, SC | 1 |
| Kurpad, C | 1 |
| Rhines, LD | 1 |
| Sampath, P | 1 |
| Tyler, BM | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Stine, L | 1 |
| Mitchell, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
12 trials available for o(6)-benzylguanine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Topics: Brain Neoplasms; Child; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2018 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Central Nervous System | 2004 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Topics: Adult; Aged; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Guanine; Humans; Middle Aged; O(6)-Me | 1998 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
18 other studies available for o(6)-benzylguanine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors.
Topics: Animals; Brain Neoplasms; Glioblastoma; Guanine; Magnetic Resonance Imaging; Magnetics; Mice; Mice, | 2014 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Deoxyguanosine; Drug Resistanc | 2004 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Cell Count; | 1994 |
Enhancing effect of O6-alkylguanine derivatives on chloroethylnitrosourea cytotoxicity toward tumor cells.
Topics: Animals; Brain Neoplasms; Cell Survival; Drug Synergism; Guanine; HeLa Cells; Humans; Nimustine; Rat | 1994 |
Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Drug Synergism | 1993 |
The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.
Topics: Biogenic Polyamines; Brain Neoplasms; Carmustine; Cell Hypoxia; Combined Modality Therapy; Drug Resi | 1993 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
[Study on potentiation of nitrosourea-cytotoxicity by DNA repair enzyme inhibitors in human brain tumor cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Drug Resis | 1997 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; | 1996 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
Topics: Animals; Brain Neoplasms; Cricetinae; Dose-Response Relationship, Drug; Female; Glioma; Guanine; Hum | 1990 |